Rare CTR9 variants and myeloid malignancies

Kyle Vogan

DOI: https://doi.org/10.1038/s41588-024-01671-4

IF: 30.8

2024-02-14

Nature Genetics

Abstract:Large-scale population-based exome sequencing studies are providing insights into the contribution of rare protein-coding variants to disease risk. Leveraging whole-exome sequencing data from the UK Biobank, Zhou et al. performed gene-based collapsing burden analyses to identify rare variants that contribute to inherited risk of myeloid malignancies. Among the genes harboring a significant enrichment of predicted deleterious variants across individuals who developed acute myeloid leukemia, myelodysplastic syndrome or myeloproliferative neoplasms was CTR9 , a gene that was previously implicated in Wilms tumor susceptibility. Functional studies in primary human hematopoietic stem and progenitor cells showed that partial loss of CTR9 function resulted in expansion of hematopoietic stem cells and could cooperate with mutations in other key driver genes such as TET2 and ASXL1 . At the molecular level, partial loss of CTR9 function was associated with increased activity of the super elongation complex, resulting in increased transcriptional elongation of genes required for hematopoietic stem cell renewal. Phenome-wide association analyses in the UK Biobank also hint at a broader role for rare CTR9 variants in contributing to risk of polycythemia vera and potentially other cancers. Original reference: Cell https://doi.org/10.1016/j.cell.2023.12.016 (2024)

genetics & heredity